Biotech Values

[lgonber]

Agree with the article in ACHN potencial, and adding value to BMY or ABBV un getting better combos ( cheaper and por lower weeks of treatments)
On the other side, I believe RGLS drug will never reach the market. I dont see the subcutaneus injection if by the time there will be a crowded market with oral drugs